About the Company
We do not have any company description for Poseida Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Poseida Therapeutics, Inc.
Poseida Therapeutics, Inc. Announces Agreement to be Acquired ... - Nasdaq
--Poseida Therapeutics, Inc., a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare ...
Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run ...
Poseida Therapeutics, Inc. has gained 179.2% since the start of the year compared to the 1.5% move for the Zacks Medical sector and the -6.3% return for the Zacks Medical - Biomedical and Genetics ...
Poseida Therapeutics Opens Enrollment in a Phase 1 Study of BCMA ...
Poseida’a open-label, multicenter, single ascending dose, Phase 1 study will assess the safety of P-BCMA-101 in up to 40 subjects with relapsed and/or refractory multiple myeloma.
Poseida Therapeutics Announces Strategic Investment by Astellas and ...
SAN DIEGO, Aug. 7, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and ...
Poseida Therapeutics, Inc. (PSTX) Moves to Buy: Rationale Behind the ...
Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche ...
Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4 ...
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche ...
News provided by Poseida Therapeutics, Inc. Nov 26, 2024, 1:10 AM ET Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non ...
Similar Companies
Loading the latest forecasts...